CONTEXT: Announcement from Gilead that analyses of three real-world data sets (2 US and 1 global) showed remdesivir lowered the risk of mortality in hospitalised COVID patients. The studies included just over 98,000 patients. Remdesivir was approved by the FDA for treatment of COVID back in October of 2020.
IMPACT: low
READ TIME: 2 mins
Quality Level Mean [1 – 10]: 6
1. “In doing so, the Phoenix-based, 30-hospital health system is looking to create the infrastructure for a hybrid healthcare strategy that includes a robust remote patient monitoring platform.”
2. “Home News Features Podcasts Research White Papers & Webcasts Events Healthcare Policy Virtual Care Predictive Analytics Healthcare Consumerism Biotech and Life Sciences Real Word Data Proves Effectiveness of Remdesivir; Weill Cornell Launches $1.5B Precision Medicine Campaign New data shows that remdesivir is effective at reducing the risk of mortality for COVID-19 patients.”
3. “READ MORE BANNER HEALTH LAUNCHES DIGITAL HEALTH PROGRAM TO SUPPORT PROVIDERS As providers become more comfortable with prescribing connected health services, healthcare organizations are creating their own formularies and giving their doctors a menu of preferred mHealth apps, devices, and solutions.”
4. ““Our patients want a higher level of access,” particularly in the wake of the COVID-19 pandemic, says Jeff Johnson, Banner’s vice president of innovation and clinical health.”
SOURCE: – gileads-remdesivir-lowers-risk-of-mortality-in-covid-19-patients